Regression trials (depicted in Figure 5A) were initiated at 13 weeks, when the mice already had appreciable tumor burden, and continued to a defined endpoint 2 weeks later (15 weeks), when most untreated animals have succumbed to hypoglycemia attributable to increased insulin secretion from the multiple pancreatic tumors that develop. This evidence concerns the gene INS and neoplasm.